Literature DB >> 26061231

Hypnotics and the Occurrence of Bone Fractures in Hospitalized Dementia Patients: A Matched Case-Control Study Using a National Inpatient Database.

Hiroyuki Tamiya1, Hideo Yasunaga2, Hiroki Matusi2, Kiyohide Fushimi3, Sumito Ogawa1, Masahiro Akishita1.   

Abstract

BACKGROUND: Preventing falls and bone fractures in hospital care is an important issue in geriatric medicine. Use of hypnotics is a potential risk factor for falls and bone fractures in older patients. However, data are lacking on the association between use of hypnotics and the occurrence of bone fracture.
METHODS: We used a national inpatient database including 1,057 hospitals in Japan and included dementia patients aged 50 years or older who were hospitalized during a period of 12 months between April 2012 and March 2013. The primary outcome was the occurrence of bone fracture during hospitalization. Use of hypnotics was compared between patients with and without bone fracture in this matched case-control study.
RESULTS: Of 140,494 patients, 830 patients suffered from in-hospital fracture. A 1:4 matching with age, sex and hospital created 817 cases with fracture and 3,158 matched patients without fracture. With adjustment for the Charlson comorbidity index, emergent admission, activities of daily living, and scores for level walking, a higher occurrence of fractures were seen with short-acting benzodiazepine hypnotics (odds ratio, 1.43; 95% confidence interval, 1.19-1.73; P<0.001), ultrashort-acting non-benzodiazepine hypnotics (1.66; 1.37-2.01; P<0.001), hydroxyzine (1.45; 1.15-1.82, P=0.001), risperidone and perospirone (1.37; 1.08-1.73; P=0.010). Other drug groups were not significantly associated with the occurrence of in-hospital fracture.
CONCLUSIONS: Short-acting benzodiazepine hypnotics and ultrashort-acting non-benzodiazepine hypnotics may increase risk of bone fracture in hospitalized dementia patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26061231      PMCID: PMC4465524          DOI: 10.1371/journal.pone.0129366

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Bone fracture following falls in hospitalized patients is an unresolved problem in geriatric medical management. Older patients, especially dementia patients, have higher risks of delirium, insomnia and day—night reversal with environmental changes related to hospital admission. Hypnotics and psychoactives are sometimes used to relieve these symptoms. Studies have examined the risk of hypnotic drug use on fall and fracture. In a meta-analysis of 22 studies, fall was significantly associated with use of sedatives and hypnotics, neuroleptics and antipsychotics, antidepressants, and benzodiazepines, but was not associated with narcotics [1]. A retrospective analysis of 3683 patients demonstrated that fall was associated with use of hypnotics [2]. Several studies showed that zolpidem was significantly associated with a higher risk of fall and fracture [3, 4]. Another study showed a hip fracture risk associated with non-benzodiazepine hypnotics [5]. These previous studies were mostly performed in nursing homes or in the community in older patients. Falls in the acute care hospital setting occur at a higher rate than falls in nursing home settings [6-9]. Moreover, hospital falls are also most frequent in safety incident reports, and sometimes lead to negligence suits [10]. However, to our knowledge, there has been no study that simultaneously assessed various types of hypnotics and their risk of in-hospital fracture in a nationwide clinical setting. In this study, we performed a matched case-control study to analyze the association between use of various types of hypnotics and the occurrence of bone fracture in hospitalized dementia patients, using a national inpatient database in Japan. We focused on dementia for several reasons. First, older patients with dementia have a fall risk twice or more than that of older patients without dementia [11, 12]. Second, older patients with dementia also have three to eight times more injuries with falls and more often have a bad prognosis [13-15]. Third, wandering, as well as other behavioral and psychological symptoms of dementia, along with hypnotic and psychoactive agents used to relieve these symptoms, increases fall risks [16, 17]. The medications tend to become the problem in acute care hospitals in trying to prevent falls in dementia patients.

Methods

Setting and Participants

For this study, we used the Diagnosis Procedure Combination database. The details of the database have been described elsewhere [18-20]. Briefly, the database includes administrative claims data and discharge abstract data, collected from about 1000 participating hospitals across Japan. The database includes the following information: patient age and sex; main diagnoses, comorbidities at admission and complications after admission recorded according to the International Classification of Diseases, 10th Revision (ICD-10) and text data in Japanese; medical procedures; medicines and devices used; length of stay; activities of daily life (ADL) scores at admission; and discharge status. A unique identifier was used for each hospital. All patient identifiers were removed from this database. Because of the anonymous nature of the data, the Institutional Review Board of The University of Tokyo waived the need for written informed consent from the participants. Study approval was also obtained from the Institutional Review Board of The University of Tokyo. Among approximately 7 million inpatients over 12 months between April 1, 2012 and March 31 2013, we identified patients aged 50 years or older. Of these, we selected patients who were diagnosed with dementia or dementia-related diseases, including dementia in Alzheimer disease (ICD-10 code, F00), vascular dementia (F01), dementia in Pick disease (F02.0, G31.0), dementia in Creutzfeldt—Jakob disease (F02.1, G810), dementia in Huntington disease (F02.2, G10), dementia in Parkinson disease (F02.3, G20), dementia in human immunodeficiency virus disease (F02.4, B220), dementia in other specified diseases classified elsewhere (F02.8), unspecified dementia (F03), alcoholic dementia (F107), dementia in cerebral lipidosis (F028, E756), Lewy bodies dementia (F028, G318), and mild cognitive disorder (F06.7). We extracted data on the following 17 types of hypnotics (or sedatives used as hypnotics) for each patient: benzodiazepine anxiolytics; diazepam; ultrashort-acting benzodiazepine hypnotics; short-acting benzodiazepine hypnotics; middle- to long-acting benzodiazepine hypnotics; ultrashort-acting non-benzodiazepine hypnotics; melatonin-receptor agonists; hydroxyzine; phenothiazine antipsychotics; haloperidol; sulpiride; risperidone and perospirone; multi-acting-receptor-targeted antipsychotics used as a hypnotic; antidepressants used as a hypnotic; Japanese kampo herbal medicine used as a hypnotic and in the treatment of behavioral and psychological symptoms of dementia; and other neurological drugs used as hypnotics. Comorbidities were assessed by ICD-10 codes and converted into scores to calculate the Charlson comorbidity index (CCI) based on Quan’s algorithm [21]. ADL scores for walking on a flat floor were also extracted including bedridden (Score 0), totally assisted (Score 1), partially assisted (Score 2) and without disability (Score 3).

Outcomes

The outcome in this study was in-hospital fracture. In the database, comorbidities already present at admission are clearly differentiated from complications that occurred after admission. In-hospital fracture was defined as fracture that occurred after admission and was determined according to the following ICD-10 codes: fracture of skull and facial bones (S02); fracture of neck (S12); fracture of rib(s), sternum and thoracic spine (S22); fracture of lumbar spine and pelvis (S32); fracture of shoulder and upper arm (S42); fracture of forearm (S52); fracture at wrist and hand level (S62); fracture of femur (S72); fracture of lower leg, including ankle (S82); fracture of foot, except ankle (S92); fractures involving multiple body regions (T02); fracture of spine, level unspecified (T08); fracture of upper limb, level unspecified (T10); and fracture of lower limb, level unspecified (T12).

Statistical Analyses

We performed a matched case—control study. First, we identified cases with in-hospital fracture. For each case, we selected four controls of similar age (±5 years) and the same sex from the same hospital. When there were more than four matched-control candidates to each case, we randomly selected four control patients. Specifically, control cases were sorted by randomly generated values from a Microsoft SQL server and the top four were selected. There are two ways to conduct matching: matching with replacement; and matching without replacement [22]. Matching with replacement means that controls can be used as matches for more than one treated individual; matching without replacement signifies that controls cannot be used as matches for more than one treated individual. Though the statistical analysis becomes more complex, matching with replacement can often decrease bias because controls that resemble many treated individuals can be used multiple times [23, 24]. Moreover, the order of matching the treated individuals is immaterial in the case of matching with replacement. One methodological paper compared matching with and without replacement in three matching methods, and it found that matching with replacement had a smaller bias among all three methods [25]. Thus, we chose matching with replacement for the present study. If a control case was a candidate for more than one case, we included both matches. In the following analysis, one control was selected three times, 95 controls were selected twice, and they were weighted using frequency weights. If the number of matched-control candidates for each case was less than four, we also included both the corresponding case (62 cases) and control (138 controls) in the analytical group subset to avoid selection bias, unless no control subjects were assigned (13 cases). Descriptive statistics were presented for the matched patients. Categorical variables were compared using the chi square test. We performed multivariable logistic regression for the occurrence of in-hospital fractures fitted with a generalized estimating equation to account for the clustered nature of the cases and controls. There are two ways to cluster in matched case-control studies: generalized estimating equations (GEEs) and conditional logistic analysis. Both methods can make consistent estimates. As GEE is more robust in terms of the specification of matching effect, we chose GEEs [26]. The dependent variable was in-hospital fracture, and independent variables included, emergent admission, ADL score for walking on a flat floor, CCI and 17 classes of drugs. All statistical analyses were conducted using IBM SPSS version 22.0 (IBM SPSS, Armonk, NY, USA).

Results

Among 140,494 eligible patients, 830 patients suffered from in-hospital fracture. Using 1:4 matching, we obtained a case group of 817 patients and a control group of 3158 patients. Table 1 shows the baseline characteristics of the matched patients (n = 3975). As a result of matching, there was no significant difference in age (P = 0.582) or sex (P = 0.728) between the case and control groups. To exclude the possibility that controls may have been matched to cases with a larger age difference than to cases with a smaller age difference, we also compared the distribution of age in the case and control groups. Mean, median, standard deviation, range and interquartile range of age (years) in the case and control groups were 81.5 vs. 81.8, 82.0 vs. 82.0, 7.9 vs. 7.5, 50–103 vs. 50–103, 11.0 vs. 10.0, respectively. The age distributions of the case and control groups were also similar. No significant difference in CCI or emergent admission was present between the cases and controls. The ADL score for walking on a flat floor on admission was significantly different between the groups.
Table 1

Characteristics of patients in the matched case and control groups.

Cases (n = 817)Controls (n = 3158) P
Charlson comorbidity index014117.3%52616.7%0.971
126432.3%101332.1%
219924.4%80525.5%
311514.1%43513.8%
≥49812.0%37912.0%
Emergent admission41550.8%153848.7%0.286
ADL score (walking on flat floor)0 (bedridden)45956.3%177356.3%0.001
1 (totally assisted)597.2%2086.6%
2 (partially assisted)10512.9%38212.1%
3 (without disability)11313.9%58818.7%
Unknown819.9%2076.5%
Table 2 shows 17 types of hypnotics (or sedatives used as hypnotics) used for the case and the control groups. The most frequently used drugs in both groups were ultrashort-acting non-benzodiazepine hypnotics, followed by short-acting benzodiazepine hypnotics. The proportion of patients who used any of the 17 types of drugs was significantly higher in the case than the control group (66.8% vs. 51.9%, P<0.001) (Table 2). The proportion of patients who used more than three types of hypnotics (or sedatives used as hypnotics) was also higher in the case than the control group (24.2% vs. 14.6%, P<0.001). The case group was significantly more likely to use benzodiazepine anxiolytics; ultrashort-acting benzodiazepine hypnotics; short-acting benzodiazepine hypnotics; middle- to long-acting benzodiazepine hypnotics; ultrashort-acting non-benzodiazepine hypnotics; melatonin-receptor agonists; hydroxyzine; phenothiazine antipsychotic; haloperidol; sulpiride; risperidone and perospirone; multi-acting-receptor-targeted antipsychotics used as a hypnotic; and an antidepressant used as a hypnotic. The proportion of patients who used Japanese kampo herbal medicine was not significantly different between the cases and controls.
Table 2

Comparison of drug use between matched case and control groups.

Case (n = 817)Control (n = 3158) P
benzodiazepine anxiolytic9812.0%2798.8%0.006
diazepam465.6%1715.4%0.809
ultrashort-acting benzodiazepine hypnotic242.9%551.7%0.029
short-acting benzodiazepine hypnotic17321.2%46014.6%<0.001
middle- to long-acting benzodiazepine hypnotic577.0%1595.0%0.029
ultrashort-acting non-benzodiazepine hypnotic19423.7%46114.6%<0.001
melatonin-receptor agonist344.2%832.6%0.021
hydroxyzine11914.6%2889.1%<0.001
phenothiazine antipsychotic253.1%581.8%0.029
haloperidol12415.2%3149.9%<0.001
sulpiride263.2%541.7%0.008
risperidone and perospirone14417.6%34310.9%<0.001
multi-acting-receptor-targeted antipsychotics used as hypnotic779.4%2176.9%0.013
antidepressant used as hypnotic506.1%1033.3%<0.001
Japanese kampo herbal medicine used as hypnotic and in treatment of BPSD506.1%1926.1%0.966
other neurological drugs used as hypnotic313.8%912.9%0.178
Number of drugs
 027133.2%151948.1%<0.001
 120124.6%74623.6%
 214718.0%43313.7%
 ≥319824.2%46014.6%
Table 3 shows the results of the multivariable logistic regression analysis. A higher occurrence of in-hospital fracture was significantly associated with use of a short-acting benzodiazepine hypnotic, an ultrashort-acting non-benzodiazepine hypnotic, a hydroxyzine, risperidone and perospirone. Neither melatonin agonists nor Japanese kampo herbal medicine was associated with the occurrence of in-hospital fracture.
Table 3

Generalized estimating equation analysis result.

odds ratio95% confidence intervalP
Type of admission
 Non-emergentReference
 Emergent1.030.881.200.712
ADL score of walking on flat floor
 0 (bedridden)Reference
 1 (totally assisted)1.010.751.370.924
 2 (partially assisted)1.000.791.270.989
 3 (without disability)0.670.540.850.001
 Unknown1.421.081.860.011
Charlson comorbidity index
 0Reference
 10.910.721.160.461
 20.880.691.120.296
 30.930.711.220.609
 ≥40.910.681.220.526
benzodiazepine anxiolytic1.150.901.470.250
diazepam0.910.651.290.608
ultrashort-acting benzodiazepine hypnotic1.530.942.500.086
short-acting benzodiazepine hypnotic1.431.191.730.000
middle- to long-acting benzodiazepine hypnotic1.010.701.450.977
ultrashort-acting non-benzodiazepine hypnotic1.661.372.010.000
melatonin-receptor agonist1.250.841.880.273
hydroxyzine1.451.151.820.001
phenothiazine antipsychotic1.060.572.000.847
haloperidol1.160.911.480.244
sulpiride1.570.952.570.077
risperidone and perospirone1.361.081.730.010
multi-acting-receptor-targeted antipsychotics used as hypnotic1.070.791.440.654
antidepressant used as hypnotic1.380.971.980.077
Japanese kampo herbal medicine0.720.521.000.052
other neurological drugs used as hypnotic1.100.621.960.736

Discussion

The present study showed an increased risk for in-hospital fracture with several hypnotics and psychoactives used as hypnotics in dementia patients who were admitted to acute care hospitals. In-hospital fracture risk was associated with a short-acting benzodiazepine hypnotic, an ultrashort-acting non-benzodiazepine hypnotic, and risperidone and perospirone. A previous US study of nursing home residents demonstrated a fracture risk with ultrashort-acting non-benzodiazepine hypnotics [5]. The present study also showed a risk with ultrashort-acting non-benzodiazepine hypnotics. A new finding in the present study is that shorter-acting drugs had relatively higher odds ratios for in-hospital fracture than longer-acting drugs. A possible explanation for this may be that patients are more likely to fall when drowsy soon after taking hypnotics. Another possible reason is that physicians may have avoided prescribing long-acting hypnotics for frail patients. To our knowledge, the present study is the first to show that hydroxyzine may increase the risk of fracture in dementia patients. Hydroxyzine has been shown to be as effective as bromazepam, one of the benzodiazepines, in the treatment of generalized anxiety disorder [27]. Because hydroxyzine has a half-life of around 3 hours, it may act like a short-acting benzodiazepine. Our results showed that a melatonin agonist was not significantly associated with the occurrence of in-hospital fracture. Melatonin-receptor agonists including ramelteon are new types of hypnotics. They act on the GABAA receptor-independent pathway in contrast to most of hypnotics that act on the GABAA receptor. The present study suggests that a melatonin agonist may be safer than other hypnotics in terms of fall and fracture risk. Japanese kampo herbal medicines, which are often used as sedatives or hypnotics in Japan, have beneficial effects on the behavioral and psychological symptoms of dementia [28-30]. Our results suggest that these drugs would be good alternatives to conventional hypnotics or sedatives in dementia patients and may reduce fracture risk. This study has several limitations. First, recorded diagnoses in an administrative claims database are less well validated than those in planned prospective studies. Second, the time interval between drug administration and related in-hospital fracture cannot be identified from the database and its causal relationship remains to be clarified. We have information on the timing and use of these agents, but not on the timing of fracture. Consequently, we are not certain as to whether the agent was prescribed before or after the fracture, or if it was not used for a short period of time for weeks to months prior to fracture. Third, it is difficult to distinguish the deleterious effect of hypnotic use itself from underlying conditions, including night delirium and insomnia requiring prescription of hypnotics. Fourth, there was no information about previous falls, and so we were unable to examine this relationship owing to the lack of data. In light of these findings, it is preferable to avoid prescribing short-acting benzodiazepines and ultrashort-acting non-benzodiazepine hypnotics, risperidone or perospirone, hydroxyzine, or multi-acting-receptor-targeted antipsychotics to in-hospital dementia patients. Melatonin-receptor agonists or Japanese kampo herbal medicine may be preferable to these drugs.

Conclusion

Short-acting benzodiazepines and ultrashort-acting non-benzodiazepine hypnotics were associated with an increase in in-hospital fractures in dementia patients, while no significant association with an increase in in-hospital fractures was seen with middle- to long-acting benzodiazepine hypnotics, melatonin-receptor agonists, or Japanese kampo herbal medicine.
  28 in total

Review 1.  A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2008-05-30       Impact factor: 2.373

2.  Risk factors for falls of hospitalized stroke patients.

Authors:  J A Tutuarima; J H van der Meulen; R J de Haan; A van Straten; M Limburg
Journal:  Stroke       Date:  1997-02       Impact factor: 7.914

3.  Risk of falls for hospitalized patients: a predictive model based on routinely available data.

Authors:  P Halfon; Y Eggli; G Van Melle; A Vagnair
Journal:  J Clin Epidemiol       Date:  2001-12       Impact factor: 6.437

4.  Predictors of fall-related injuries among community-dwelling elderly people with dementia.

Authors:  T Asada; T Kariya; T Kinoshita; A Asaka; S Morikawa; M Yoshioka; T Kakuma
Journal:  Age Ageing       Date:  1996-01       Impact factor: 10.668

5.  Risk factors for falls among elderly persons living in the community.

Authors:  M E Tinetti; M Speechley; S F Ginter
Journal:  N Engl J Med       Date:  1988-12-29       Impact factor: 91.245

Review 6.  Meta-analysis of the impact of 9 medication classes on falls in elderly persons.

Authors:  John C Woolcott; Kathryn J Richardson; Matthew O Wiens; Bhavini Patel; Judith Marin; Karim M Khan; Carlo A Marra
Journal:  Arch Intern Med       Date:  2009-11-23

7.  Falls in dementia patients.

Authors:  P T van Dijk; O G Meulenberg; H J van de Sande; J D Habbema
Journal:  Gerontologist       Date:  1993-04

8.  Hospital falls: a persistent problem.

Authors:  V R Morgan; J H Mathison; J C Rice; D I Clemmer
Journal:  Am J Public Health       Date:  1985-07       Impact factor: 9.308

9.  Falls and fractures in patients with Alzheimer-type dementia.

Authors:  D M Buchner; E B Larson
Journal:  JAMA       Date:  1987-03-20       Impact factor: 56.272

10.  Risk of falling and hypnotic drugs: retrospective study of inpatients.

Authors:  Kyoko Obayashi; Takuya Araki; Katsunori Nakamura; Masahiko Kurabayashi; Yoshihisa Nojima; Katsuyuki Hara; Tomonori Nakamura; Koujirou Yamamoto
Journal:  Drugs R D       Date:  2013-06
View more
  12 in total

Review 1.  Zolpidem use and risk of fractures: a systematic review and meta-analysis.

Authors:  S M Park; J Ryu; D R Lee; D Shin; J M Yun; J Lee
Journal:  Osteoporos Int       Date:  2016-04-22       Impact factor: 4.507

2.  Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies.

Authors:  Kathryn Richardson; George M Savva; Penelope J Boyd; Clare Aldus; Ian Maidment; Eduwin Pakpahan; Yoon K Loke; Antony Arthur; Nicholas Steel; Clive Ballard; Robert Howard; Chris Fox
Journal:  Health Technol Assess       Date:  2021-01       Impact factor: 4.014

Review 3.  Hypnotics with novel modes of action.

Authors:  Daniel Hoyer; Andrew Allen; Laura H Jacobson
Journal:  Br J Clin Pharmacol       Date:  2020-01-17       Impact factor: 4.335

4.  The Association Between Central Nervous System-Active Medication Use and Fall-Related Injury in Community-Dwelling Older Adults with Dementia.

Authors:  Laura A Hart; Zachary A Marcum; Shelly L Gray; Rod L Walker; Paul K Crane; Eric B Larson
Journal:  Pharmacotherapy       Date:  2019-04-08       Impact factor: 4.705

5.  Association between comprehensive geriatric assessment and polypharmacy at discharge in patients with ischaemic stroke: A nationwide, retrospective, cohort study.

Authors:  Tatsuya Hosoi; Hayato Yamana; Hiroyuki Tamiya; Hiroki Matsui; Kiyohide Fushimi; Masahiro Akishita; Hideo Yasunaga; Sumito Ogawa
Journal:  EClinicalMedicine       Date:  2022-06-25

6.  Point Prevalence Survey of Benzodiazepine and Sedative-Hypnotic Drug Use in Hospitalized Adult Patients.

Authors:  Heather L Neville; Mia Losier; Jennifer Pitman; Melissa Gehrig; Jennifer E Isenor; Laura V Minard; Ellen Penny; Susan K Bowles
Journal:  Can J Hosp Pharm       Date:  2020-06-01

7.  Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer's Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant.

Authors:  Carsten T Beuckmann; Hiroyuki Suzuki; Erik S Musiek; Takashi Ueno; Toshitaka Sato; Masahiro Bando; Yoshihide Osada; Margaret Moline
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

8.  Rigid Cooperation of Per1 and Per2 proteins.

Authors:  Hiroyuki Tamiya; Sumito Ogawa; Yasuyoshi Ouchi; Masahiro Akishita
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

Review 9.  Hospital outcomes of older people with cognitive impairment: An integrative review.

Authors:  Carole Fogg; Peter Griffiths; Paul Meredith; Jackie Bridges
Journal:  Int J Geriatr Psychiatry       Date:  2018-06-26       Impact factor: 3.485

10.  The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.

Authors:  Shih-Pei Shen; Yanfang Liu; Hong Qiu; Kuan-Yi Tsai; Hung-Chi Wu; Wen-Miin Liang; Meng Shu; Frank Huang-Chih Chou
Journal:  PLoS One       Date:  2019-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.